Sun Recalls Nimodipine Capsules on Crystallization Concerns

Sun Pharmaceutical is recalling one lot of its 30-mg nimodipine after a customer complaint about possible crystallization of the solution inside the capsule. The effects of crystallized nimodipine are unclear, the FDA said, though no adverse events have been reported. The company was not available for comment on the root cause of the recall.
Drug Industry Daily